e-Therapeutics PLC (LSE:ETX) - Share price


Stock Report

e-Therapeutics PLC ETX

Last Price
GBX3.10

Day Change
0.00|0.00%

As of 19/07/2019
16:15:28 BST | GBX
Minimum 15 Minutes Delay.

Last Close3.10p
Day Range3.03 - 3.25
Mkt Cap8.34Mil
52-Wk Range1.40 - 8.65
Yield %-
ISINGB00B2823H99
Volume1,274,370
P/E-2.08
P/S1.94
P/CF-0.02

Share Price

Total Returns 19/07/2019

 Chg (%)  
More ...
e-Therapeutics PLC93.75 
FTSE 100 TR GBP1.56
 
Financials
201720182019
More ...
Income Statement
Turnover0.000.000.04
Operating Profit-14.23-6.77-5.11
Net Profit-13.13-5.36-4.00
Reported EPS-4.91-2.00-1.49
Balance Sheet
Current Assets17.7211.567.35
Non Current Assets0.210.210.16
Total Assets17.9311.767.51
Current Liabilities1.951.020.71
Total Liabilities---
Total Equity15.9810.746.80
Cash Flow
Operating Cash Flow-12.01-7.37-5.05
Net Change in Cash-1.872.62-1.19

Regulatory News

DateAuthor Headline
24/11/2014Emma Wall Woodford to Launch Second Fund
Six months after the successful launch of his equity income fund, veteren investor Neil Woodford is considering a global smaller companies fund 
14/07/2014Emma Wall Woodford's Full Portfolio Revealed
Woodford is maximising his overseas exposure and allocating a third of the portfolio to his favourite sector, pharmaceuticals, as well as a surprisingly high financials exposure
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
09/07/2019PurchaseProfessor Trevor Mervyn Jones CBE2.13258,2165,500.00
01/04/2019PurchaseMs. Christine Helen Soden2.80250,0007,000.00
01/04/2019PurchaseDr. Raymond John Barlow2.80250,0007,000.00
11/01/2019PurchaseProfessor Trevor Mervyn Jones CBE6.5184,4865,500.00

Company Profile

e-Therapeutics PLC is a drug discovery company. The company's discovery platform is based on the network of pharmacology and chemical biology. e-Therapeutics operates in a segment of drug discovery and development.

Sector

Biotechnology

Index

FTSE AIM All-Share

Next Event 04/10/2019

Half-Yearly Results
Ratios
Comp
More ...
PER (E)0.00
Div Yld (E)0.00
PEG (E)0.00
ROCE-75.18
Op Mrgn-116.23
EPS Grwth0.00
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00
Directors
More ...
Executive Director, ChairmanMr. Iain Gladstone Ross
Non-Executive DirectorMs. Christine Helen Soden
Non-Executive DirectorProfessor Trevor Mervyn Jones CBE
Executive Director, Finance Director and Interim COOMr. Steven Medlicott
Executive Director, Chief Executive OfficerDr. Raymond John Barlow
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2019 Morningstar. All rights reserved.